Orthopediatrics Corp ( (KIDS) ) has released its Q2 earnings. Here is a breakdown of the information Orthopediatrics Corp presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
OrthoPediatrics Corp., a company dedicated to pediatric orthopedics, continues to make strides in the medical field with a comprehensive range of products aimed at improving the lives of children with orthopedic conditions. The company operates in the healthcare sector, focusing on trauma, deformity, scoliosis, and sports medicine procedures, and distributes its products globally.
In the second quarter of 2025, OrthoPediatrics achieved a milestone by surpassing $60 million in revenue for the first time, reaching $61.1 million, which represents a 16% increase from the previous year. The company also reported a significant 58% increase in adjusted EBITDA, highlighting strong performance across its core business segments.
Key financial metrics from the quarter include a 17% increase in domestic revenue and a 12% increase in international revenue. The company’s scoliosis segment saw a remarkable 35% growth, while trauma and deformity revenue grew by 10%. Despite a net loss of $7.1 million, the company improved its non-GAAP diluted loss per share to ($0.11) from ($0.23) the previous year. Additionally, OrthoPediatrics expanded its Specialty Bracing Division and entered new international markets.
Looking ahead, OrthoPediatrics has raised its full-year 2025 revenue guidance, projecting growth between 16% and 18% compared to 2024. The company remains optimistic about achieving its adjusted EBITDA targets and generating positive free cash flow by the fourth quarter of 2025, setting the stage for a potential breakeven in free cash flow by 2026.